Computational studies for pre-evaluation of pharmacological profile of gut microbiota-produced gliclazide metabolites
2024

Studying Gliclazide Metabolites from Gut Microbiota

publication Evidence: moderate

Author Information

Author(s): Đanić Maja, Pavlović Nebojša, Zaklan Dragana, Stanimirov Bojan, Lazarević Slavica, Al-Salami Hani, Mikov Momir

Primary Institution: Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia

Hypothesis

This study aimed to conduct a pharmacoinformatic analysis of gliclazide metabolites produced by gut microbiota and assess their docking potential with the SUR1 receptor.

Conclusion

The study suggests that hydroxylated gut microbiota-produced gliclazide metabolites should be further investigated as potential drug candidates with improved characteristics compared to the parent drug.

Supporting Evidence

  • All studied metabolites exhibited better intrinsic solubility than gliclazide.
  • Hydroxylated metabolites M1-M6 showed the most pronounced polar and hydrophilic properties.
  • Docking analysis revealed that four hydroxyl-metabolites showed the highest binding affinity to the SUR1 receptor.

Takeaway

Researchers looked at how certain substances made by gut bacteria from a diabetes drug might work better than the drug itself.

Methodology

The study involved screening ten potential gliclazide metabolites for pharmacological properties, performing molecular docking analysis with the SUR1 receptor, and evaluating drug-likeness properties using various software.

Limitations

The specific microbial species involved in gliclazide metabolism were not identified, limiting understanding of which bacterial populations are responsible for the observed metabolic changes.

Digital Object Identifier (DOI)

10.3389/fphar.2024.1492284

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication